{"Answer": "Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer\n\nAdjuvant therapy with an aromatase inhibitor improves outcomes , as compared with tamoxifen , in postmenopausal women with hormone-receptor -- positive breast cancer .\n\nIn two phase 3 trials , we randomly assigned premenopausal women with hormone-receptor -- positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years . Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin , oophorectomy , or ovarian irradiation . The primary analysis combined data from 4690 patients in the two trials .\n\nAfter a median follow-up of 68 months , disease-free survival at 5 years was 91.1 % in the exemestane -- ovarian suppression group and 87.3 % in the tamoxifen -- ovarian suppression group ( hazard ratio for disease recurrence , second invasive cancer , or death , 0.72 ; 95 % confidence interval ( CI ) , 0.60 to 0.85 ; P ( 0.001 ) . The rate of freedom from breast cancer at 5 years was 92.8 % in the exemestane -- ovarian suppression group , as compared with 88.8 % in the tamoxifen -- ovarian suppression group ( hazard ratio for recurrence , 0.66 ; 95 % CI , 0.55 to 0.80 ; P ( 0.001 ) . With 194 deaths ( 4.1 % of the patients ) , overall survival did not differ significantly between the two groups ( hazard ratio for death in the exemestane -- ovarian suppression group , 1.14 ; 95 % CI , 0.86 to 1.51 ; P = 0.37 ) . Selected adverse events of grade 3 or 4 were reported for 30.6 % of the patients in the exemestane -- ovarian suppression group and 29.4 % of those in the tamoxifen -- ovarian suppression group , with profiles similar to those for postmenopausal women .\n\nIn premenopausal women with hormone-receptor -- positive early breast cancer , adjuvant treatment with exemestane plus ovarian suppression , as compared with tamoxifen plus ovarian suppression , significantly reduced recurrence . ( Funded by Pfizer and others ; TEXT and SOFT ClinicalTrials . gov numbers ,  NCT00066703  and  NCT00066690  , respectively . )\n\n", "Topic": "breast", "Question": "NEJMoa1404037", "level": 0, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "adverse event": ["Outcomes"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "adverse event": ["Adverse-effects"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "A"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Age": [], "Condition": ["A"], "Location": [], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Intensity": [], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["A"], "Conclusion-general": ["A"]}, "Count": 1}, "Doggos_text": {"Sex": "The participants were women.", "Condition": "The participants were premenopausal and had hormone-receptor positive early breast cancer.", "Sample-size": "There were 4690 patients.", "Intervention-general": "The study assessed the impact of exemestane with ovarian suppression.", "Duration": "Participants received the intervention for a period of 5 years.", "Control": "A comparison group was assigned tamoxifen plus ovarian suppression.", "Outcomes-general": "The study assessed the recurrence of breast cancer and the survival of patients.", "Effect-strength": "The rate of freedom from breast cancer at 5 years was 92.8% in the examestane group, and 88.8% in the tamoxifen group. The disease-free survival at 5 years was 91.1% in the examestane group and 87.3% in the tamoxifen group. Overall survival did not differ significantly between the two groups.", "Adverse-effects": "Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the examestane group and 29.4% of the tamoxifen group.", "Conclusion-general": "In pre-menopausal women with hormone-receptor early breast cancer, treatment with examestane plus ovarian suppression significantly reduced the recurrence of cancer when compared with treatment with tamoxifen with ovarian suppression."}, "id": "NEJMoa1404037", "children": [{"Answer": "Pre-menopausal women with hormone-receptor positive (HRP) breast cancer have another promising treatment available to them to reduce recurrence of the disease.  Adjuvant Exemestane with an aromatase inhibitor, or hormone receptor, is shown to improve outcomes, as compared to tamoxifen plus ovarian suppression. A five-year follow-up in the  Exemestane group showed a disease-free survival rate at 91.1 % compared to the Tamoxifen group with a 87.3% survival rate. The rate of freedom from cancer at five years was at nearly 93% in the Exemestane group as compared to about 89% in the Tamoxifen group. In the study of 4690 patients, there were 194 deaths. The overall survival rate did not differ significantly between the two groups. Adverse reactions were similar in both groups. This is great news for women looking for an alternative treatment to suppress the chance of HRP breast cancer returning.&#13;", "AssignmentId": "3WMINLGALCOLOX0EFDGC7W577LYCAK", "Question": "NEJMoa1404037", "WorkerId": "A2KROBPV0YPE4A", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "b"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["b"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK", "children": [{"Answer": "A study between Exemestane and tamoxifen was done in pre-menopausal women. In a follow up of 68 months it was shown that exemestane had a survival rate of 91.1% compared to 87.3% on the tamoxifen group without the hazardous side effects. Exemestane also showed adverse side effects of 30.6% and 29.4% with Tamoxifen. But in pre-menopausal women with hormone receptor positive early stage breast cancer, exemestane plus ovarian suppression significantly reduced recurrence of breast cancer. ", "AssignmentId": "3KIBXJ1WD6FS9Z63H92SWA2K2X0OK6", "Question": "NEJMoa1404037", "WorkerId": "A2LTOS0AZ3B28A", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "B"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["A"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3KIBXJ1WD6FS9Z63H92SWA2K2X0OK6", "children": [{"Answer": "in two phase 3 trials is was shown that exemestane helped menopausal women stay breast cancer free for a median of 5 years. Disease free survival rate was 91.1% with Exemestane as compared to 87.3% with Tamoxifen. 4690 women were studied over the 5 year period.", "AssignmentId": "37QW5D2ZRH7NCQWVF1MYQA3U4VXS8U", "Question": "NEJMoa1404037", "WorkerId": "A2LTOS0AZ3B28A", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "A"], "Intervention": ["B", "A", "B"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["A"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_37QW5D2ZRH7NCQWVF1MYQA3U4VXS8U", "children": [{"Answer": "The medications tamoxifen and exemestane were compared during drug trials. Exemestane combined with ovarian suppression is more effective.", "AssignmentId": "35DR22AR5E597ACOXUXPY1CB3UHX31", "Question": "NEJMoa1404037", "WorkerId": "A6CVN7CSC1K26", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "24-39", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["C", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_35DR22AR5E597ACOXUXPY1CB3UHX31", "children": [{"Answer": "Exemestane plus ovarian suppression treatment reduces recurrence in women", "AssignmentId": "3M68NM076ISO7XDU7XPVGM27CDNR6C", "Question": "NEJMoa1404037", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 4, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "woman": ["Participants"], "exemestane": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "woman": ["Sex"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["A", "C", "C"], "Outcomes": ["C", "C", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3M68NM076ISO7XDU7XPVGM27CDNR6C"}]}]}]}]}, {"Answer": "In premenopausal breast cancer (specifically the early, hormone receptor positive kind), treatment with a therapy called aromatase inhibitor is better than another drug called tamoxifen. They found this by studying the clinical trial data from 4690 patients from two separate trials. The 5 year survival rate was 91% for aromatase inhibitor and 87% for tamoxifen. The researchers had a fairly high confidence in that result. However, the group that was treated with the aromatase inhibitor had a slightly elevated risk for adverse side effects as opposed to those treated with the tamoxifen. In summary, the research found that women treated with adjuvant treatment with exemstane plus ovarian suppression medication were more likely to stay in remission after their breast cancer had been treated, as opposed to the tamoxifen group. This study was paid for by Pfizer and is publicly available online.", "AssignmentId": "3VHP9MDGRO5GKOHMQT24LXGY48MFCP", "Question": "NEJMoa1404037", "WorkerId": "A2WNTEVRT68JXT", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "B"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP", "children": [{"Answer": "Researchers have completed a five 5 year study on 4690 pre-menopausal women that tested positive for breast cancer.  Women were randomly assigned hormone receptors.  Out of these trials, women that received exemestane had a 91.1% survival rate and the women who received tamoxifen, which is an ovarian hormone suppresant had an 87.3% survival rate. After 5 years, 92.8% of women who received exemestane and 88.8% of women who received tamoxifen were cancer free.  Exemestane significantly reduced the frequency of breast cancer compared to tamoxifen.", "AssignmentId": "323Q6SJS8J171WS2CLG5WODEIF8HFC", "Question": "NEJMoa1404037", "WorkerId": "A2XS5QI4YX493N", "Qualification": 0.6923076923076923, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["A"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_323Q6SJS8J171WS2CLG5WODEIF8HFC", "children": [{"Answer": "Trials conducted over 5 years showed that exemestane improved outcomes for postmenopausal women with hormone-receptor positive breast cancer that were also undergoing suppression of ovarian estrogen production. Results for tamoxifen were lower. ", "AssignmentId": "3HUTX6F6VV8XSJ2DS3WOWEGQL622O4", "Question": "NEJMoa1404037", "WorkerId": "AUPHYAKC58LPA", "Qualification": 0.46153846153846156, "Topic": "breast", "Hop": 2, "Education": "Some College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["D", "A", "C"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "C", "C"], "Conclusion": ["D"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["D"]}}, "id": "NEJMoa1404037_3HUTX6F6VV8XSJ2DS3WOWEGQL622O4", "children": [{"Answer": "Adjuvant treatment with exemestane plus ovarian suppression greatly reduced recurrence of the disease in certain premenopausal women.", "AssignmentId": "3IQ1VMJRYU5JQZTB3T6L564Z21KA9T", "Question": "NEJMoa1404037", "WorkerId": "AON59V5VZU2AK", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "exemestane": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "premenopausal": ["Condition"], "woman": ["Sex"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["A", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3IQ1VMJRYU5JQZTB3T6L564Z21KA9T", "children": [{"Answer": "Use of an inhibitor with Exemestane improves outcomes of breast cancer.", "AssignmentId": "3R2PKQ87NXTD31V34Q23RQY2FI9IM1", "Question": "NEJMoa1404037", "WorkerId": "A2LTOS0AZ3B28A", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 4, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"breast cancer": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3R2PKQ87NXTD31V34Q23RQY2FI9IM1"}]}]}]}]}, {"Answer": "This study found that in postmenopausal women with hormone receptor-positive breast cancer and when compared to tamofoxifen, that adjuvant therapy with an aromatase inhibitor improves outcomes. During two phase 3 trials the primary analysis used data from 4690 patients. Ovarian estrogen production was achieved with the use of the gonadotropin releasing hormone agoinsts triptorellin, oophoroectomy, or ovarian irraditation. Findings concluded that in premenopausal women  with hormone receptor -positive breast cancer that tamoxifen plus ovarian suppression and adjuvant treatment with exemestane plus ovarian suppression ended up significantly reducing recurrence. A median follow up of 68 months disease free survival was 91.1%.The rate of freedom from breast cancer at five years was 92.8% for this group of women involved. A well executed study for the cancer researchers involved. Postmenopausal women achieved the same outcomes thus proving pre or post menopause did not matter.", "AssignmentId": "3SBEHTYCWOODXIKHNTQELLL9OTOYIA", "Question": "NEJMoa1404037", "WorkerId": "A1AZV2XOQK7RSW", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA", "children": [{"Answer": "There is new hope for pre-menopausal women with hormone-receptor positive early breast cancer. Adjuvant treatment with Exemstane plus ovarian suppression has shown a significant reduction in recurrence of the disease compared to those who used Tamoxifen.  Trial studies over a five year period of 4690 patients showed disease-free survival rates at five years in over 91% of those using Exemastane.  Survival rates in the Tamoxifen group were at 87%. The results were similar to those shown in post-menopausal studies.", "AssignmentId": "3E7TUJ2EGD7HO6WNN3XNV7C5NPMD99", "Question": "NEJMoa1404037", "WorkerId": "A2KROBPV0YPE4A", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "B"], "Outcomes": ["A", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3E7TUJ2EGD7HO6WNN3XNV7C5NPMD99", "children": [{"Answer": "Research found that treating hormone-receptor positive early breast cancer in premenopausal women with adjuvant treatment with exemestane in combination with ovarian suppression reduced the chance of a recurrence of cancer better than tamoxifen plus ovarian suppression.", "AssignmentId": "3Y54SXRO1M6MPNGN74STW7H5367UT7", "Question": "NEJMoa1404037", "WorkerId": "A3BDVHNMJECSKG", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["B", "C", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3Y54SXRO1M6MPNGN74STW7H5367UT7", "children": [{"Answer": "Adjuvant therapy with Aromatase inhibitors improves breast cancer survival.  5 year survival rate was 91.1% compared to 87.3% without.", "AssignmentId": "35GCEFQ6I69YC5C3YCLAVMSMBV5Z3S", "Question": "NEJMoa1404037", "WorkerId": "A2LTOS0AZ3B28A", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"]}, "Fine": {"5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "B", "D"], "Outcomes": ["A", "B", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["D"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_35GCEFQ6I69YC5C3YCLAVMSMBV5Z3S", "children": [{"Answer": "Exemestane significantly reduced recurrence compare with tamoxifen.", "AssignmentId": "3M68NM076ISO7XDU7XPVGM27DFY6R7", "Question": "NEJMoa1404037", "WorkerId": "A2YTQDLACTLIBA", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "60+", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["C", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3M68NM076ISO7XDU7XPVGM27DFY6R7"}]}]}]}]}, {"Answer": "In 2 phase 3 trials, randomly assigned premenopausal women w/ hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or taxoifen plus ovarian suppression for a 5-year period. Suppression of ovarian estrogen production was achieved with using gonadotropin-releasing-hormone agonist triptorelin, oophorectomy or ovarian irradiation. The primary analysis combined data from 4690 patients in 2 trials. After a median f/u of 68 months, disease-free  survival at 5 years was 91.1% in exemestane group &amp; 87.3% in tamoxifen group. The rate of no breast cancer at 5 years was 92.8% in the exemestane group &amp; 88.8% in the tamoxifen group. With 194 deaths, overall survival did not differ much between the 2 groups. Selected adverse events of grade 3 or 4 were reported for 30.6% of patients in the exemestane grp &amp; 29.4% in the tamoxifen group, similar to those for postmenopausal women. In premenopausal women with hormone-receptor, positive early breast cancer adjuvant treatment w/ exemestane plus ovarian suprression significantly reduced recurrence. ", "AssignmentId": "352YTHGROWYX3GVDS4KM5KGNTIO4HM", "Question": "NEJMoa1404037", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 0, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "adverse event": ["Outcomes"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "adverse event": ["Adverse-effects"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "A"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["A"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM", "children": [{"Answer": "In postmenopausal women with breast cancer of the hormone receptor positive variant, a study has shown that outcomes improve using Aromatase inhibitor therapy with ovarian suppression. An evaluation of the rate of disease free survival after a median time increment of 68 months revealed that the group of ovarian suppression plus Tamoxifen patients had a 87.3% rate compared with the Exemestane plus ovarian suppression group at 91.1% disease free survival group. Survival rates all together revealed no significant differences in the two groups. ", "AssignmentId": "3K3R2QNK8CO358799YNC57GT9PQU99", "Question": "NEJMoa1404037", "WorkerId": "ADGH08WUP68ZF", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "female", "Age": "15-24", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["D", "A", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3K3R2QNK8CO358799YNC57GT9PQU99", "children": [{"Answer": "Premenopausal women with hormone-receptor-positive early breast cancer had significantly reduced recurrence with exemestane plus ovarian suppression as compared with tamoxifen plus ovarian suppression. Disease-free survival at 5 years was 91.1% versus 87.3%.", "AssignmentId": "3QUO65DNQV96CVBFBN6U2XBI4XPUOI", "Question": "NEJMoa1404037", "WorkerId": "A2YTQDLACTLIBA", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "60+", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3QUO65DNQV96CVBFBN6U2XBI4XPUOI", "children": [{"Answer": "Exemestane with ovarian suppression significantly reduced recurrence. Disease free survival was 91.1% at 5 years. ", "AssignmentId": "3B1NLC6UG0H5SDML6IUSNIFH51VPGX", "Question": "NEJMoa1404037", "WorkerId": "A2YUCJ28XANFOX", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 3, "Education": "High School", "Gender": "female", "Age": "24-39", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "A", "C"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3B1NLC6UG0H5SDML6IUSNIFH51VPGX", "children": [{"Answer": "Compared to tamoxifen, adjuvat treatment reduced recurrence of cancer more.", "AssignmentId": "3W2LOLRXLC0V6CYJ91JWQ57PEAIRKX", "Question": "NEJMoa1404037", "WorkerId": "A2ELH7YDLFNJUZ", "Qualification": 1.0, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "male", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"tamoxifen": ["Intervention"]}, "Fine": {"tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["C", "C", "B"], "Outcomes": ["C", "C", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3W2LOLRXLC0V6CYJ91JWQ57PEAIRKX"}]}]}]}]}, {"Answer": "Testing over several years has proven that an aromatase inhibitor (exemestane) improves outcomes for post-menopausal women with hormone-receptor positive breast cancer. The women all went through ovarian suppression via different methods, but survival rate after five and a half years was higher for those who went through ovarian suppression while taking exemestane than those who went through it taking tamoxifen. In addition, more women were free from breast cancer after five years that had been taking the exemestane as opposed to those who took tamoxifen. The treatment was also found to be helpful for pre-menopausal women with hormone-receptor positive early breast cancer. &#13;4690 patients were tested during these trials over more than five years, and the results indicate that the aromatase inhibitor exemestane was overall the more successful drug treatment when compared to tamoxifen and combined with suppression of ovarian estrogen production. ", "AssignmentId": "3XIQGXAUMDTR8TDBZ60FBIOR8B77XE", "Question": "NEJMoa1404037", "WorkerId": "AUPHYAKC58LPA", "Qualification": 0.46153846153846156, "Topic": "breast", "Hop": 0, "Education": "Some College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "C", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE", "children": [{"Answer": "A study was done involving 4690 premenopausal women with hormone-receptor -- positive breast cancer. One group of the women received exemestane plus ovarian suppression; the other group received tamoxifen plus ovarian suppression. Both groups were treated for a period of 5 years. Disease-free survival at 5 years was 91.1 % in the exemestane with ovarian suppression group compared to 87.3 % in the tamoxifen plus ovarian suppression group. Overall, treatment with exemestane plus ovarian suppression significantly reduced recurrence.", "AssignmentId": "3HL8HNGX46MEMQAJE9SDJ7FQZ2IF92", "Question": "NEJMoa1404037", "WorkerId": "A3D8ZG1VV5FO35", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3HL8HNGX46MEMQAJE9SDJ7FQZ2IF92", "children": [{"Answer": "Premenopausal Breast Cancer outcomes are improved using Exemestane combined with ovarian suppression in women suffering from hormone receptor positive early stage breast cancer. The disease free survival rate was 4% higher in the Exemestane group then the Tamoxifen group. ", "AssignmentId": "3EA3QWIZ4JGHGWLNDN3FD4TU9BUITX", "Question": "NEJMoa1404037", "WorkerId": "ADGH08WUP68ZF", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 2, "Education": "Some College", "Gender": "female", "Age": "15-24", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["B", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3EA3QWIZ4JGHGWLNDN3FD4TU9BUITX", "children": [{"Answer": "Adjuvant therapy with an aromatase inhibitor improves treatment outcomes in patients with early breast cancer over tamoxifen. ", "AssignmentId": "3Y4W8Q93L05FLD9QQ42JNP12EY9DVR", "Question": "NEJMoa1404037", "WorkerId": "A35F1LYW2ZXWLT", "Qualification": 0.6153846153846154, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "24-39", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "breast cancer": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"early breast cancer": ["Condition"], "breast cancer": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["B", "C", "C"], "Intervention": ["B", "C", "B"], "Outcomes": ["C", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3Y4W8Q93L05FLD9QQ42JNP12EY9DVR", "children": [{"Answer": "Adjuvant therapy with an aromatse inhibitor outcomes, reduced recurrence.", "AssignmentId": "3RJSC4XJ11F4OZTH81WB4KNK8UP05O", "Question": "NEJMoa1404037", "WorkerId": "A3F6TS7I3CSUM8", "Qualification": 0.6923076923076923, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "male", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {}, "Fine": {}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3RJSC4XJ11F4OZTH81WB4KNK8UP05O"}]}]}]}]}, {"Answer": "Adjuvant therapy with an aromatase inhibitor improves outcomes when compared to tamokifen, in postmenopausal women with hormone-receptor positive breast cancer. Trials were done in which women with hormone receptor positive early breast cancer were assigned to one of two groups, those with the aromatase inhibitor or those with tamokifen. These trials lasted for a period of five years. A total of 4,690 patients were studied in two trials that contained three phases per trial. At the 68 month follow up, disease free survival was found to be higher in the aromatase inhibitor group over the tamokifen group with a confidence interval of 95%. The rate of freedom from breast cancer was higher in the aromatase inhibitor group than the tamokifen group. With a death rate of 4.1%, overall survival did not differ significantly between the two groups. Adverse events were reported at a higher rate in the group with the aromatase inhibitor than the group with tamokifen.", "AssignmentId": "3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ", "Question": "NEJMoa1404037", "WorkerId": "AWCD7E12GSX2Z", "Qualification": 0.6153846153846154, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "adverse event": ["Outcomes"]}, "Fine": {"early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "adverse event": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "D", "A"], "Intervention": ["C", "A", "B"], "Outcomes": ["A", "B", "B"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["A"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ", "children": [{"Answer": "This was a study comparing two types of treatments, Adjuvant therapy with an aromatase inhibitor and tamoxifen, and the it showed that adjuvent therapy with an aromatase inhibitor improves outcomes when compared to tamoxifen. The trial went on for 5 years, randomly assigned women were given one of the two drugs over this time period, the results were after 5 years the  cancer free survival of women who took adjuvant therapy with an aromatase inhibitor was 91.1%, compared to the women who took tamoxifen, whos cancer free survival rate was 87.3%.", "AssignmentId": "3Z7ISHFUH1GKD2I9ATG6M30XR1Z8ZZ", "Question": "NEJMoa1404037", "WorkerId": "A3CDWPBKYDDASL", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "female", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["B", "A", "A"], "Outcomes": ["B", "A", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3Z7ISHFUH1GKD2I9ATG6M30XR1Z8ZZ", "children": [{"Answer": "In this content we see about how incubators and hormone receptor plays an important role to improve the health condition of the patient who suffer from breast cancer.they closely watched and improve their health quality by using hormone receptor and exemestane.  ", "AssignmentId": "3PM8NZGV8Z11EBIQV59LB95MDI7QX1", "Question": "NEJMoa1404037", "WorkerId": "A1RVRSK2GTUVGK", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"breast cancer": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "B", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["C"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3PM8NZGV8Z11EBIQV59LB95MDI7QX1", "children": [{"Answer": "Premenopause women with early hormone +ve breast cancer treated with ovary suppression survived better if given exemestane not tamoxifen.", "AssignmentId": "3IJXV6UZ1Y440H8V9YYKDPSCLY9RIL", "Question": "NEJMoa1404037", "WorkerId": "A31FD3QCYZ28Q2", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 3, "Education": "Some College", "Gender": "male", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["A", "C", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3IJXV6UZ1Y440H8V9YYKDPSCLY9RIL", "children": [{"Answer": "Breast cancer can be cured by the hormone receptor", "AssignmentId": "3RRCEFRB7NXNC3SRSCAQJ9DPZ2S4BA", "Question": "NEJMoa1404037", "WorkerId": "A1RVRSK2GTUVGK", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"breast cancer": ["Outcomes"]}, "Fine": {"breast cancer": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["B", "C", "C"], "Intervention": ["C", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["D"]}, "Fine": {"Sex": ["C"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["D"]}}, "id": "NEJMoa1404037_3RRCEFRB7NXNC3SRSCAQJ9DPZ2S4BA"}]}]}]}]}, {"Answer": "Studies have shown improved patient outcomes in postmenopausal women with hormone-receptor positive breast cancer who received adjuvant therapy with an aromatase inhibitor as compared to tamoxifen. In two phase 3 randomized controlled trials of nearly 4700 premenopausal women with hormone-receptor positive breast cancer, adjuvant therapy with exemestane in combination with ovarian suppression showed significantly higher rates of disease-free survival at 5 years and freedom from breast cancer at 5 years as compared to tamoxifen in combination with ovarian suppression. The rates of overall survival as well as grade 3 or 4 adverse effects were not significantly different among the two groups. The results of these two trials in premenopausal women support those of previously published studies examining the effects of adjuvant aromatase inhibitors compared to tamoxifen in postmenopausal women with hormone-receptor positive breast cancer.", "AssignmentId": "31LM9EDVOMDFGU09Y923G622XW5NJX", "Question": "NEJMoa1404037", "WorkerId": "A3K7OKFT05A073", "Qualification": 1.0, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "male", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "C", "B"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["B"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX", "children": [{"Answer": "In 2 phase 3 trials premenopausal women were randomly assigned hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for 5 yrs. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation.  4690 patients were used in 2 trials. Adjuvant therapy w/ exemestane plus ovarian suppression reduced recurrence compared to tamoxifen plus ovarian suppression.", "AssignmentId": "3NJM2BJS4XRSB16G4WY9XRU27U8CPL", "Question": "NEJMoa1404037", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3NJM2BJS4XRSB16G4WY9XRU27U8CPL", "children": [{"Answer": "A group of premenopausal women were tested over 5 years, the women were randomly assigned one of two drugs, tamoxifen or exemestane. After 5 years the results from the test show that in premenopausal women ememestane has the higher disease survival rate with 91.1%.", "AssignmentId": "3KIBXJ1WD6FS9Z63H92SWA2K28GKO4", "Question": "NEJMoa1404037", "WorkerId": "A3CDWPBKYDDASL", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "Some College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "91.1 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "91.1 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["B", "A", "B"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3KIBXJ1WD6FS9Z63H92SWA2K28GKO4", "children": [{"Answer": "Exemestane more significantly reduced breast cancer recurrence than tamoxifen in premenopausal women with certain early breast cancers.", "AssignmentId": "3RJSC4XJ11F4OZTH81WB4KNK7MF502", "Question": "NEJMoa1404037", "WorkerId": "AAB13RUHSABEV", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"early breast cancer": ["Condition"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["B", "B", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3RJSC4XJ11F4OZTH81WB4KNK7MF502", "children": [{"Answer": "Exemestane plus ovarian suppression greatly reduced recurrence of cancer.", "AssignmentId": "3300DTYQT32S8BR900JTNKKFYROEQ3", "Question": "NEJMoa1404037", "WorkerId": "A3P57IUDHUKNCE", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 4, "Education": "Some College", "Gender": "male", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "exemestane": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3300DTYQT32S8BR900JTNKKFYROEQ3"}]}]}]}]}, {"Answer": "We have an extraordinary study of the benefits of using Adjuvant Exemestane with ovarian suppression in premenopausal breast cancer compared to patients using Tamoxifen with ovarian suppression. In the study, primary analysis combined data from 4690 patients in two trials.  In 2 phase 3 trials,  randomly assigned premenopausal women (a woman usually in her 40s have menstrual irregularity experience menopause symptoms)  with hormone-receptor early breast cancer to the aromatase inhibitor exemestan plus ovarian suppression or tamoxifen plus ovarian suppression, suppression of the ovarian estrogen was achieved with the used of gonadotropin-releasing hormone agonist triptorelin, oophorectomy or ovarian irradiation.&#13;&#13;In the follow up of 5 years, we had disease-free survival of exemestane 91.1% compared to tamoxifen 87.3%. The freedom of breast cancer at 5yrs, exemestane was 92.8% compared to tamoxifen 88.8%. With deaths of 4.1%, there wasn't much difference between the two groups.  In conclusion, patients using exemestane had significantly reduced recurrence compared to tamoxifen.", "AssignmentId": "3JCG6DTRV4BH5EHE9RETH19TG3SQQO", "Question": "NEJMoa1404037", "WorkerId": "A3MV3MK1DR9MNZ", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "A", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["A"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO", "children": [{"Answer": "In post-menopausal women with hormone receptor positive early breast cancer, adjuvant therapy with an aromatase inhibitor improves outcome, as compared with tamoxifen .  In two trials, pre-menopausal women with the same diagnosis were randomly assigned to the aromastase inhibitor treatment or tamoxifen for 5 years.  Conclusion: In pre-menopausal women with hormone receptor positive early breast cancer, adjuvant treatment, as compared with tamoxifen, significantly improved outcome as well.", "AssignmentId": "3E47SOBEYRH0UFJCR18POUTQLGJCIF", "Question": "NEJMoa1404037", "WorkerId": "AAB13RUHSABEV", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["B", "B", "A"], "Outcomes": ["C", "B", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3E47SOBEYRH0UFJCR18POUTQLGJCIF", "children": [{"Answer": "Premenopausal women with hormone-receptor -- positive early breast cancer, treated with exemestane have a 91. 1 % disease-free survival rate at 5 years compared to those treated with tamoxifen who have a 87.3 % rate. Exemestane significantly reduced recurrence.", "AssignmentId": "3D4CH1LGEBEK0Q6EPTYV1SF20TL9GM", "Question": "NEJMoa1404037", "WorkerId": "A3D8ZG1VV5FO35", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "40-60", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "5 year": ["Intervention"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"early breast cancer": ["Condition"], "5 year": ["Duration"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "B", "B"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3D4CH1LGEBEK0Q6EPTYV1SF20TL9GM", "children": [{"Answer": "Premenopausal women with hormone receptor + early breast ca adjuvant treatment with exemestane plus ovarian suppression reduced recurrence", "AssignmentId": "3SKRO2GZ72C7D7Z2B74HKEPC9AZ1KH", "Question": "NEJMoa1404037", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 3, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "exemestane": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "premenopausal": ["Condition"], "woman": ["Sex"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["A", "C", "C"], "Outcomes": ["C", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3SKRO2GZ72C7D7Z2B74HKEPC9AZ1KH", "children": [{"Answer": "In two trials adjuvant therapy is more effective than tamoxifen.", "AssignmentId": "34J10VATJGJ4OGTVWJ9K8ZI7QKWQIP", "Question": "NEJMoa1404037", "WorkerId": "AXY0D2AMLKE2A", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "male", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"tamoxifen": ["Intervention"]}, "Fine": {"tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["C", "C", "B"], "Outcomes": ["C", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_34J10VATJGJ4OGTVWJ9K8ZI7QKWQIP"}]}]}]}]}]}